Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina. Show more
4020 Stirrup Creek Drive, Durham, NC, 27703, United States
Start AI Chat
Market Cap
78.99M
52 Wk Range
$9.00 - $54.29
Previous Close
$24.41
Open
$26.50
Volume
4,496
Day Range
$22.35 - $26.50
Enterprise Value
83.92M
Cash
14.2M
Avg Qtr Burn
-15.26M
Insider Ownership
51.84%
Institutional Own.
34.40%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Xeglyze/Abametapir (Metalloproteinase Inhibitor) Details Head Lice Infestation | Approved Update |